Monoamine-based treatments for depression have evolved greatly over the past several
years, but shortcomings such as suboptimal efficacy, treatment lag, and residual cognitive …

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering
from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or …

Autism is a neurodevelopmental disorder in which the first diagnostic symptom is unusual
reciprocal social interactions. Approximately half of the children diagnosed with an autism …

Angelman syndrome (AS) is a neurodevelopmental disorder largely due to abnormal
maternal expression of the UBE3A gene leading to the deletion of E6-associated protein. AS …

Anxiety disorders are amongst the most common and disabling of psychiatric illnesses and
have severe health and socio-economic implications. Despite the availability of a number of …

Org 26576 acts by modulating ionotropic AMPA-type glutamate receptors to enhance
glutamatergic neurotransmission. The aim of this Phase 1b study (N= 54) was to explore …

Drug-induced respiratory depression (DIRD) is a common problem encountered post-
operatively and can persist for days after surgery. It is not always possible to predict the …

BACKGROUND: It has been posited that glutamate dysregulation contributes to the
pathophysiology of attention-deficit/hyperactivity disorder (ADHD). Modulation of glutamate …

In rats, as in humans, normal aging is characterized by a decline in hippocampal-dependent
learning and memory, as well as in glutamatergic function. Both growth hormone (GH) and …

Progress toward pharmacological means for enhancing memory and cognition has been
retarded by the widely discussed failure of behavioral studies in animals to predict human …